This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
Pharma ETF (FTXH) Hits New 52-Week High
by Sanghamitra Saha
Pharma ETF FTXH hits a new 52-week high as industry momentum, rate cuts, and AI adoption lift the sector???signaling potential near-term upside for FTXH investors.
Pharma ETFs in Spotlight Following Robust Q3 Earnings Results
by Aparajita Dutta
Pharma ETFs like IHE and PPH are rallying as strong Q3 earnings across major pharmaceutical companies lift sector sentiment.
Shine a Light on Healthcare ETFs Amid National Alzheimer's Awareness Month
by Aparajita Dutta
As National Alzheimer's Awareness Month spotlights new treatments, healthcare ETFs like XLV and VHT might gain fresh investor appeal.
ETFs to Watch Post JNJ's Q3 Earnings Surprise & Bullish Outlook
by Aparajita Dutta
JNJ's Q3 earnings beat and raised 2025 sales outlook could lift healthcare ETFs like IHE, XLV and IYH, heavily weighted toward the drugmaker.
Trump Slams 100% Tariff on Imported Drugs: Pharma ETFs Take a Hit
by Aparajita Dutta
Trump's 100% tariff on imported drugs jolts markets, slamming pharma giants and dragging ETFs like XPH, FTXH, IHE, and PPH lower.
ETFs to Gain on JNJ's Solid Q1 Earnings & Upbeat Outlook
by Sweta Killa
IHE, PPH, XLV, IYH and FTXH could gain as JNJ lifts 2025 outlook and dividend after strong Q2 earnings beat.
Pharma ETFs in Focus on Trump's Drug Price Overhaul
by Sweta Killa
Trump's plan to slash the price of prescription drugs by 30% put pharma ETFs in focus.
A Look at Pharma ETFs After Strong Q1 Earnings
by Sweta Killa
Many pharma bigwigs reported solid results, with some beating on earnings or revenues or both.
ETFs in Focus Post JNJ's Q1 Earnings Beat, Dividend Hike
by Sweta Killa
Johnson & Johnson reports strong first-quarter 2025 results, raises revenue guidance and boosts its quarterly dividends.
ETFs in Focus Post JNJ Q3 Earnings Beat, Target Price Hike
by Sweta Killa
Johnson & Johnson infused positive optimism after posting solid third-quarter 2024 earnings. A few analysts raised their target price on the stock.